Navigation Links
Neurocrine Biosciences Reports Third Quarter 2013 Results
Date:10/29/2013

s in 280 women with heavy uterine bleeding due to uterine fibroids.

VMAT2 UpdateThe Company has completed enrollment in Kinect 2, a Phase IIb study of its VMAT2 inhibitor, NBI-98854. This study is a 90 subject, placebo-controlled, double-blind, parallel-design, multiple-dose, six-week study assessing NBI-98854 in doses up to 75mg once-a-day against placebo in tardive dyskinesia patients with underlying mood disorders, schizophrenia and schizoaffective disorders, and gastrointestinal disorders. The primary endpoint is the Abnormal Involuntary Movement Scale (AIMS) at the end of the six weeks of dosing. The video AIMS will be scored by blinded central reviewers who are movement disorder neurologists. This study recently completed screening and randomization of subjects, and top-line data from this study is expected in December of 2013.

In 2014, the Company intends to initiate another clinical study of NBI-98854 in tardive dyskinesia patients. This study is currently in the design phase, and the results of the Kinect and Kinect 2 Studies will serve to inform the ultimate design of this clinical trial. The primary endpoint in this study will be the AIMS assessed by blinded central reviewers who are movement disorder neurologists.

The Company is currently completing two Phase I studies for NBI-98854 assessing drug-drug interactions as well as the impact of hepatic impairment on drug metabolism.

Additionally, the Company is conducting preclinical studies to support the advancement of NBI-98854 into clinical trials for individuals suffering from Tourette's syndrome. Upon successful completion of these preclinical studies, the Company anticipates entering Phase I and Phase II clinical studies in 2014.

Conference Call and Webcast Today at 5:00PM Eastern Time
Neurocrine will hold a live conference call and webcast today at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Participants can access the live conference call by dialing 866-952
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Neurocrine Biosciences Reports Second Quarter 2013 Results
2. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2013 Financial Results
3. Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
4. Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
5. Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
6. Neurocrine Biosciences Reports Third Quarter 2012 Results
7. Neurocrine Biosciences Reports Second Quarter 2012 Results
8. Neurocrine Biosciences to Present at The 24th Annual Roth Conference
9. Neurocrine Biosciences to Present at the Citi 2012 Global Health Care Conference
10. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
11. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014 Philadelphia’s newest entrepreneurial incubation space ... their start. The Innovation Center @3401 , a collaborative ... City Science Center to help attract and nurture start-up ... July 28. , The Innovation Center @3401 ... Market Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... SILVER SPRING, Md., July 29, 2014  United ... today announced its financial results for the ... "Our continued growth shows that our medicines ... from pulmonary arterial hypertension (PAH)," said Martine ... Executive Officer. "The commercial launch this quarter ...
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a ... of the Top 10 Plastic Surgeon Specialists for Nashville, TN ... His complete line includes a Hydration Booster, Retexturing Night Crème, ... and skin a younger, more radiant appearance while protecting them ... different, that is why at Dr. J. J. Wendel Plastic ...
(Date:7/28/2014)... , July 28, 2014 Sapphire Energy, ... today announced the appointment of biotechnology veteran James ... board of directors. Levine replaces Cynthia ,CJ, Warner, who ... will remain chairman of the company,s board of directors. ... Energy,s mission to deliver commercial scale algae-based fuels has ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... When semiconductor nanorods are exposed to light, ... clustering nanorods together, physicists at the University of ... is increased dramatically providing new insight into this ... by associate professor Marija Drndic,s group, including graduate ...
... June 23, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (" China-Biotics ... (NASDAQ: CHBT ), a leading developer, manufacturer, and ... 20, 2011, the Company received a letter from the NASDAQ Listing ... Company has not yet filed its Annual Report on Form 10-K ...
... Biosciences, Inc. (NASDAQ: NBIX ) announced today that ... a Notice of Allowance for the Company,s proprietary Vesicular Monoamine ... that a composition of matter patent on NBI-98854 will have ... Additionally, on June 17, 2011, the Company held a ...
Cached Biology Technology:Penn physicists observe 'campfire effect' in blinking nanorod semiconductors 2Penn physicists observe 'campfire effect' in blinking nanorod semiconductors 3China-Biotics, Inc. Receives NASDAQ Delisting Notification 2China-Biotics, Inc. Receives NASDAQ Delisting Notification 3Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor 2Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor 3
(Date:7/29/2014)... you,ve ever ordered the wrong food at a restaurant, don,t ... have less to do with what you want and more ... analyzing 217 menus and the selections of over 300 diners, ... Journal of Hospitality Management showed that when it comes ... what you see on the menu and how you imagine ...
(Date:7/29/2014)... of Ascension Island, one of the world,s largest green ... Writing in the journal Biodiversity and Conservation , ... Government Conservation Department report that the number of green ... increased by more than 500 per cent since records ... are now estimated to be laid on the Island,s ...
(Date:7/29/2014)... of Kent has shown for the first time how ... that could have a major impact on cancer therapy ... uncovered the mechanism whereby the physical properties of the ... are ,fine-tuned, to undertake different functions. , While ... providing a framework for the cell, others are more ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Major turtle nesting beaches protected in 1 of the UK's far flung overseas territories 2
... CA July 12, 2012 Readers of the top-ranked scientific ... noticed a recent wave of articles, most recently in the ... importance for biology and medicine. These papers, all published this ... of Professor Raymond Stevens, illuminate a large and medically important ...
... century ago, the South Pole was one of Earth,s last ... activity. Led by Monash University,s Professor Steven Chown, a ... out the current and future conservation challenges facing the Antarctic ... . The team analysed the effectiveness of the existing ...
... trying to control the invasive tamarisk plant have been ... a rapidly evolving beetle that has been changing its ... Their findings, in a paper titled "Evolution of critical ... Diorhabda carinulata , a biological control agent against ...
Cached Biology News:Large, medically important class of proteins starts to yield its secrets 2Large, medically important class of proteins starts to yield its secrets 3Large, medically important class of proteins starts to yield its secrets 4Large, medically important class of proteins starts to yield its secrets 5Large, medically important class of proteins starts to yield its secrets 6Large, medically important class of proteins starts to yield its secrets 7The challenges facing the vulnerable Antarctic 2Tamarisk biocontrol efforts get evolutionary boost 2Tamarisk biocontrol efforts get evolutionary boost 3
... Flat bottoms,• Nonreversible ... to reduce contamination,• Individual ... identification,• Uniform footprint for ... for optimal cell attachment,• ...
Rabbit polyclonal to GABA A Receptor gamma 2 ( Abpromise for all tested applications). entrezGeneID: 2566 SwissProtID: P18507...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
Biology Products: